Source: Mediterranee Infection

Abstract

Background.

SARS-CoV-2 infection can cause significant mortality among dependant elderly residents living within medical retirements homes. Objectives. To report the results of SARS-CoV-2 PCR-based screening campaigns conducted in dependent elderly resident in retirement homes in Marseille, France and the follow-up of positive cases.

Methods.

Data of 1690 elderly residents and 992 member staffs were retrospectively collected through interview of the medical team of 23 retirement homes and electronic health recording system of the hospital.

Results.

Elderly residents were predominantly female (64.8%) with a mean age of 83 years old. SARS-CoV-2 detection in residents (226, 13.4%) was significantly higher than in staff members (87, 8.8%), with p=4.10-4 . Of 226 infected residents, 37 (16.4%) were detected on a case-by-case basis because of COVID-19 symptoms and 189 (83.6%) were detected through mass screening; 84.0% had possible COVID-19 symptoms, including respiratory symptoms and signs (48.5%) and fever (47.2%); 118 (52.2%) patients received a course of oral hydroxychloroquine and azithromycin (HCQ-AZ) for at least 3 days; and 47 (20.8%) died. In multivariate, death rate was positively associated with being male (31.5% vs. 13.4%, OR=4.33, p<10-4 ) and being older than 85 years (26.1% vs. 15.7%, OR=3.01, p=0.005) and negatively associated with being diagnosed through mass screening (16.9%, vs. 40.5%, OR=0.20, p<10-4 ) and receiving HCQ-AZ treatment for at least 3 days (14.4% vs. 27.8%, OR=0.41, p=0.017).

Conclusion.

Our data shows that early diagnosis and care of COVID-19 patients at retirement homes can be effective in saving lives.





Related:

61 studies (37 peer reviewed) Early treatment studies are very positive – COVID deaths: 621, 206

China Study of 2882 patients: Beneficial effects exerted by hydroxychloroquine in treating COVID-19 patients via protecting multiple organs

The effect of 5-day course of hydroxychloroquine and azithromycin combination on QT interval in non-ICU COVID19(+) patients

Share on facebook
Share on twitter
Share on whatsapp
On Trend

Latest Stories

Dr. Harvey Risch: Hydroxychloroquine, Ivermectin, and Other Therapeutics Highly Effective in Early COVID Treatment

I’ve railed against this in the media that we are a part of, and the way that the propaganda reacts to this is, “Ignore it. Ignore all of this.” I’m saying this now because the general public has to be the one that gets angry. The general public should be furious at the way people have been treated in the country by suppression of these drugs, by that kind of website that suppresses the ability of doctors to practice medicine.

Read More »

A Judge Stands up to a Hospital: “Step Aside” and Give a Dying Man Ivermectin

The judge’s finest moment may have been when he dashed the most glaring myth about ivermectin—that it is not safe, despite decades of use that shows otherwise. Noting that all drugs have side effects, Judge Fullerton listed ivermectin’s effects from a government website.
“(N)umber one, generally well tolerated; number two, dizziness; number three, pruritus; number four, nausea/diarrhea. These are the side effects for the dosage that’s being asked to be administered,” he said. “The risks of these side effects are so minimal that Mr. Ng’s current situation outweighs that risk by one-hundredfold.”

Read More »